vs

Side-by-side financial comparison of ACACIA RESEARCH CORP (ACTG) and Akebia Therapeutics, Inc. (AKBA). Click either name above to swap in a different company.

Akebia Therapeutics, Inc. is the larger business by last-quarter revenue ($57.6M vs $50.1M, roughly 1.1× ACACIA RESEARCH CORP). On growth, Akebia Therapeutics, Inc. posted the faster year-over-year revenue change (23.9% vs 2.6%). Over the past eight quarters, ACACIA RESEARCH CORP's revenue compounded faster (43.6% CAGR vs 32.9%).

Acacia Research Corporation is a publicly traded American company based in New York City. It acquires and operates businesses in industries including the technology, energy, and industrial/manufacturing sectors. Acacia has a strategic relationship with Starboard Value, LP, the company's controlling shareholder. The company has been characterized as a patent troll.

Akebia Therapeutics is a biopharmaceutical company dedicated to developing and commercializing novel therapies for patients with kidney diseases, particularly anemia linked to chronic kidney disease. It operates across global markets, focusing on addressing unmet medical needs in the nephrology care segment.

ACTG vs AKBA — Head-to-Head

Bigger by revenue
AKBA
AKBA
1.1× larger
AKBA
$57.6M
$50.1M
ACTG
Growing faster (revenue YoY)
AKBA
AKBA
+21.3% gap
AKBA
23.9%
2.6%
ACTG
Faster 2-yr revenue CAGR
ACTG
ACTG
Annualised
ACTG
43.6%
32.9%
AKBA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACTG
ACTG
AKBA
AKBA
Revenue
$50.1M
$57.6M
Net Profit
$3.4M
Gross Margin
12.8%
78.2%
Operating Margin
-26.1%
-14.8%
Net Margin
6.8%
Revenue YoY
2.6%
23.9%
Net Profit YoY
125.5%
EPS (diluted)
$0.03
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACTG
ACTG
AKBA
AKBA
Q4 25
$50.1M
$57.6M
Q3 25
$59.4M
$58.8M
Q2 25
$51.2M
$62.5M
Q1 25
$124.4M
$57.3M
Q4 24
$48.8M
$46.5M
Q3 24
$23.3M
$37.4M
Q2 24
$25.8M
$43.6M
Q1 24
$24.3M
$32.6M
Net Profit
ACTG
ACTG
AKBA
AKBA
Q4 25
$3.4M
Q3 25
$-2.7M
$540.0K
Q2 25
$-3.3M
$247.0K
Q1 25
$24.3M
$6.1M
Q4 24
$-13.4M
Q3 24
$-14.0M
$-20.0M
Q2 24
$-8.4M
$-8.6M
Q1 24
$-186.0K
$-18.0M
Gross Margin
ACTG
ACTG
AKBA
AKBA
Q4 25
12.8%
78.2%
Q3 25
21.2%
84.0%
Q2 25
12.8%
84.1%
Q1 25
47.4%
86.7%
Q4 24
17.6%
56.2%
Q3 24
10.1%
62.2%
Q2 24
26.2%
60.9%
Q1 24
49.2%
64.4%
Operating Margin
ACTG
ACTG
AKBA
AKBA
Q4 25
-26.1%
-14.8%
Q3 25
-10.8%
7.6%
Q2 25
-24.2%
22.6%
Q1 25
30.8%
23.6%
Q4 24
-32.4%
-30.8%
Q3 24
-44.1%
-33.4%
Q2 24
-18.4%
-20.0%
Q1 24
-8.6%
-45.8%
Net Margin
ACTG
ACTG
AKBA
AKBA
Q4 25
6.8%
Q3 25
-4.6%
0.9%
Q2 25
-6.4%
0.4%
Q1 25
19.5%
10.7%
Q4 24
-27.5%
Q3 24
-60.0%
-53.5%
Q2 24
-32.7%
-19.7%
Q1 24
-0.8%
-55.2%
EPS (diluted)
ACTG
ACTG
AKBA
AKBA
Q4 25
$0.03
$-0.05
Q3 25
$-0.03
$0.00
Q2 25
$-0.03
$0.00
Q1 25
$0.25
$0.03
Q4 24
$-0.14
$-0.10
Q3 24
$-0.14
$-0.10
Q2 24
$-0.08
$-0.04
Q1 24
$0.00
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACTG
ACTG
AKBA
AKBA
Cash + ST InvestmentsLiquidity on hand
$306.7M
$184.8M
Total DebtLower is stronger
$91.9M
$48.3M
Stockholders' EquityBook value
$543.5M
$32.6M
Total Assets
$771.0M
$376.6M
Debt / EquityLower = less leverage
0.17×
1.48×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACTG
ACTG
AKBA
AKBA
Q4 25
$306.7M
$184.8M
Q3 25
$301.8M
$166.4M
Q2 25
$316.7M
$137.3M
Q1 25
$272.0M
$113.4M
Q4 24
$273.9M
$51.9M
Q3 24
$410.9M
$34.0M
Q2 24
$441.9M
$39.5M
Q1 24
$498.4M
$42.0M
Total Debt
ACTG
ACTG
AKBA
AKBA
Q4 25
$91.9M
$48.3M
Q3 25
$47.6M
Q2 25
$47.1M
Q1 25
$46.5M
Q4 24
$38.7M
Q3 24
$38.4M
Q2 24
$38.0M
Q1 24
$30.1M
Stockholders' Equity
ACTG
ACTG
AKBA
AKBA
Q4 25
$543.5M
$32.6M
Q3 25
$537.6M
$41.6M
Q2 25
$538.6M
$29.2M
Q1 25
$540.2M
$24.6M
Q4 24
$514.8M
$-49.2M
Q3 24
$540.2M
$-50.4M
Q2 24
$560.7M
$-33.8M
Q1 24
$568.3M
$-27.3M
Total Assets
ACTG
ACTG
AKBA
AKBA
Q4 25
$771.0M
$376.6M
Q3 25
$768.9M
$364.2M
Q2 25
$775.5M
$345.6M
Q1 25
$801.6M
$310.2M
Q4 24
$756.4M
$220.7M
Q3 24
$707.6M
$207.1M
Q2 24
$753.6M
$220.2M
Q1 24
$631.7M
$225.5M
Debt / Equity
ACTG
ACTG
AKBA
AKBA
Q4 25
0.17×
1.48×
Q3 25
1.15×
Q2 25
1.61×
Q1 25
1.89×
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACTG
ACTG
AKBA
AKBA
Operating Cash FlowLast quarter
$75.2M
$31.1M
Free Cash FlowOCF − Capex
$31.1M
FCF MarginFCF / Revenue
53.9%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
22.01×
TTM Free Cash FlowTrailing 4 quarters
$67.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACTG
ACTG
AKBA
AKBA
Q4 25
$75.2M
$31.1M
Q3 25
$9.5M
$28.1M
Q2 25
$50.1M
$22.3M
Q1 25
$2.4M
$-13.6M
Q4 24
$50.1M
$-4.5M
Q3 24
$-593.0K
$-6.7M
Q2 24
$16.1M
$-10.1M
Q1 24
$54.8M
$-19.4M
Free Cash Flow
ACTG
ACTG
AKBA
AKBA
Q4 25
$31.1M
Q3 25
$28.0M
Q2 25
$22.2M
Q1 25
$335.0K
$-13.6M
Q4 24
$-98.5M
$-4.5M
Q3 24
$-2.8M
$-6.7M
Q2 24
$-126.7M
$-10.1M
Q1 24
$54.6M
FCF Margin
ACTG
ACTG
AKBA
AKBA
Q4 25
53.9%
Q3 25
47.7%
Q2 25
35.6%
Q1 25
0.3%
-23.7%
Q4 24
-201.8%
-9.6%
Q3 24
-12.1%
-17.9%
Q2 24
-490.5%
-23.1%
Q1 24
224.4%
Capex Intensity
ACTG
ACTG
AKBA
AKBA
Q4 25
0.1%
Q3 25
0.1%
Q2 25
0.2%
Q1 25
1.7%
0.0%
Q4 24
304.4%
0.0%
Q3 24
9.6%
0.0%
Q2 24
553.0%
0.1%
Q1 24
1.1%
0.0%
Cash Conversion
ACTG
ACTG
AKBA
AKBA
Q4 25
22.01×
Q3 25
52.05×
Q2 25
90.47×
Q1 25
0.10×
-2.22×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACTG
ACTG

Energy Operations$16.0M32%
Transportation Safety$10.4M21%
Office Storage And Display Solutions$8.4M17%
Printers Consumables And Parts$6.5M13%
Natural Gas Reserves$5.1M10%
Natural Gas Liquids Reserves$3.3M7%

AKBA
AKBA

Auryxia$48.1M84%
Vafseo$6.2M11%
License Collaboration And Other Revenue$3.3M6%

Related Comparisons